The availability of skeletal-selective myosin activators could have a great impact in the development of treatments for skeletal muscle diseases/myopathies where myosin function is disrupted directly (e.g., mutations in MYH2 (24) or in other sarcomeric proteins interacting with it (25,26)) or indirectly (e.g., sarcopenia (27)). Here, MYH2 is linked to sarcopenia.